Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder
The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are: 1. Is a single psilocybin dose feasible to administer during postoperative hospitalization? 2. Is psilocybin safe in this patient population? 3. How does psilocybin affect postoperative pain, opioid use, anxiety, and depression after hospital discharge? Participants will: Receive one oral dose of psilocybin during their postoperative inpatient stay Complete assessments of pain, mood, and opioid use during recovery
- Status
- planned
- Phase
- Phase 1
- Institution
- Trent Emerick
- Principal investigator
- Trent D. Emerick
- Start date
- 2026-07-01
- End date
- 2027-08-01
- Registry ID
- NCT07406828
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.